Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:DSCI

Derma Sciences (DSCI) Stock Price, News & Analysis

Derma Sciences logo

About Derma Sciences Stock (NASDAQ:DSCI)

Key Stats

Today's Range
$7.00
$7.00
50-Day Range
N/A
52-Week Range
$2.92
$7.05
Volume
N/A
Average Volume
719,592 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Derma Sciences, Inc. (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection. The Company's advanced wound care product line consists of MEDIHONEY, TCC-EZ, AMNIOEXCEL and AMNIOMATRIX, XTRASORB and BIOGUARD. Traditional wound care products principally consist of commodity related dressings, ointments, gauze bandages, adhesive bandages, wound closure strips, catheter fasteners and skin care products. The Company's traditional wound care product line includes branded gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages and other compression devices for the medical markets.

Receive DSCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Derma Sciences and its competitors with MarketBeat's FREE daily newsletter.

DSCI Stock News Headlines

Roivant Sciences Acquires Dermavant, Expanding Dermatology Portfolio
Dermavant Sciences Ltd.
I was wrong. Dead wrong.
Deep inside Silicon Valley the alarm bells are ringing… Jeff Bezos just sold $3 billion in Amazon stock. Warren Buffet just sold another 100 million Apple shares. Yet while the insiders are dumping shares, millions of unsuspecting investors are dumping more and more money in… blind to the carnage that’s just around the corner.
See More Headlines

DSCI Stock Analysis - Frequently Asked Questions

Derma Sciences Inc (NASDAQ:DSCI) issued its quarterly earnings data on Tuesday, August, 9th. The medical instruments supplier reported $0.08 earnings per share for the quarter, beating analysts' consensus estimates of ($0.08) by $0.16. The medical instruments supplier had revenue of $22.20 million for the quarter, compared to analysts' expectations of $22.40 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that Derma Sciences investors own include Novavax (NVAX), Progenics Pharmaceuticals (PGNX), Palatin Technologies (PTN), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Antares Pharma (ATRS) and Bellicum Pharmaceuticals (BLCM).

Company Calendar

Last Earnings
8/09/2016
Today
11/18/2024

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
Health Care Supplies
Current Symbol
NASDAQ:DSCI
CUSIP
24982750
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

This page (NASDAQ:DSCI) was last updated on 11/18/2024 by MarketBeat.com Staff
From Our Partners